Back to Directory
Icatibant
Performance & EnduranceBradykinin receptor antagonist for hereditary angioedema attacks.
Key Benefits
- ✓Treats HAE attacks
- ✓Rapidly reduces swelling
- ✓Prevents airway obstruction
- ✓Life-saving for HAE patients
- ✓Fast-acting
Dosing Information
Dosage Range
30 mg
Frequency
At attack onset, up to 3/day
Typical Duration
As needed for attacks
Detailed Protocol
Administered via subcutaneous injection in the abdomen at onset of HAE attack. Can be self-administered after training. Up to 3 doses in 24 hours if needed.
About Icatibant
Icatibant (Firazyr) is a synthetic decapeptide that competitively inhibits bradykinin B2 receptors. FDA-approved for acute treatment of hereditary angioedema (HAE) attacks. Rapidly reverses dangerous swelling episodes.
Research Notes
FDA-approved in 2011 for HAE. Clinical trials show rapid symptom resolution. Critical medication for HAE patients. Safe for self-administration.
Potential Side Effects
- •Injection site reactions (very common)
- •Nausea
- •Headache
- •Dizziness
- •Fever
Always consult with a healthcare professional before starting any peptide therapy.